公开(公告)号：JP2013049681A

公开(公告)日：2013-03-14

申请号：JP2012225875

申请日：2012-10-11

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： WAGNER ROLF ,  TUFANO MICHAEL D ,  STEWART KENT D ,  ROCKWAY TODD W ,  RANDOLPH JOHN T ,  PRATT JOHN K ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LONGENECKER KENTON L ,  LIU YAYA ,  LIU DACHUN ,  KRUEGER ALLAN C ,  KATI WARREN M ,  HUTCHINSON DOUGLAS K ,  HUANG PEGGY P ,  FLENTGE CHARLES A ,  DONNER PAMELA L ,  DEGOEY DAVID A ,  BETEBENNER DAVID A ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  SARRIS KATHY ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/513 ,  A61K31/5377 ,  A61P1/16 ,  A61P31/14 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.

Abstract translation: 待解决的问题：提供可用于治疗丙型肝炎（HCV）感染的化合物。 解决方案：在化合物中，尿嘧啶或胸腺嘧啶衍生物通过亚苯连接成稠合的2-环环系（R6），或者通过另外的两个原子连接基（L）连接到5-6元单环（R6 ）。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯基） 萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基苯乙烯基 苯基）甲磺酰胺。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：JP2013056886A

公开(公告)日：2013-03-28

申请号：JP2012221886

申请日：2012-10-04

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： FLENTGE CHARLES A ,  HUTCHINSON DOUGLAS K ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  DONNER PAMELA L ,  KATI WARREN M ,  KRUEGER ALLAN C ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61K45/00 ,  A61P31/14 ,  A61P43/00 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To provide anti-infective agents and the like, used either in combination with or in lieu of an interferon agent and/or ribavirin.SOLUTION: This invention relates to: (a) compounds and salts thereof that inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 要解决的问题：提供与干扰素和/或利巴韦林组合或代替干扰素剂和/或利巴韦林使用的抗感染剂等。 本发明涉及：（a）抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：WO2007081517A3

公开(公告)日：2007-12-21

申请号：PCT/US2006048685

申请日：2006-12-20

Applicant: ABBOTT LAB ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

Inventor： BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

IPC: C07D495/04 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D475/06 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

公开(公告)号：WO2007076034A3

公开(公告)日：2007-10-04

申请号：PCT/US2006049079

申请日：2006-12-20

Applicant: ABBOTT LAB ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

Inventor： BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

公开(公告)号：WO2010144646A2

公开(公告)日：2010-12-16

申请号：PCT/US2010038077

申请日：2010-06-10

Applicant: ABBOTT LAB ,  DEGOEY DAVID A ,  KATI WARREN M ,  HUTCHINS CHARLES W ,  DONNER PAMELA L ,  KRUEGER ALLAN C ,  RANDOLPH JOHN T ,  MOTTER CHRISTOPHER E ,  NELSON LISSA T ,  PATEL SACHIN V ,  MATULENKO MARK A ,  KEDDY RYAN G ,  JINKERSON TAMMIE K ,  SOLTWEDEL TODD N ,  HUTCHINSON DOUGLAS K ,  FLENTGE CHARLES A ,  WAGNER ROLF ,  MARING CLARENCE J ,  TUFANO MICHAEL D ,  BETEBENNER DAVID A ,  ROCKWAY TODD W ,  LIU DACHUN ,  PRATT JOHN K ,  LAVIN MICHAEL J ,  SARRIS KATHY ,  WOLLER KEVIN R ,  WAGAW SEBLE H ,  CALIFANO JEAN C ,  LI WENKE

Inventor： DEGOEY DAVID A ,  KATI WARREN M ,  HUTCHINS CHARLES W ,  DONNER PAMELA L ,  KRUEGER ALLAN C ,  RANDOLPH JOHN T ,  MOTTER CHRISTOPHER E ,  NELSON LISSA T ,  PATEL SACHIN V ,  MATULENKO MARK A ,  KEDDY RYAN G ,  JINKERSON TAMMIE K ,  SOLTWEDEL TODD N ,  HUTCHINSON DOUGLAS K ,  FLENTGE CHARLES A ,  WAGNER ROLF ,  MARING CLARENCE J ,  TUFANO MICHAEL D ,  BETEBENNER DAVID A ,  ROCKWAY TODD W ,  LIU DACHUN ,  PRATT JOHN K ,  LAVIN MICHAEL J ,  SARRIS KATHY ,  WOLLER KEVIN R ,  WAGAW SEBLE H ,  CALIFANO JEAN C ,  LI WENKE

IPC: C07D403/14

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：WO2007081517A8

公开(公告)日：2007-09-20

申请号：PCT/US2006048685

申请日：2006-12-20

Applicant: ABBOTT LAB ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

Inventor： BETEBENNER DAVID A ,  DEGOEY DAVID A ,  MARING CLARENCE J ,  KRUEGER ALLAN C ,  IWASAKI NOBUHIKO ,  ROCKWAY TODD W ,  COOPER CURT S ,  ANDERSON DAVID D ,  DONNER PAMELA L ,  GREEN BRIAN E ,  KEMPF DALE J ,  LIU DACHUN ,  MCDANIEL KEITH F ,  MADIGAN DAROLD L ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  SHANLEY JASON P ,  TUFANO MICHAEL D ,  WAGNER ROLF ,  ZHANG RONG ,  MOLLA AKHTERUZZAMAN ,  MO HONGMEI ,  PILOT-MATIAS TAMI J ,  MASSE SHERIE VL ,  CARRICK ROBERT J ,  HE WEPING ,  LU LIANGJUN ,  GRAMPOVNIK DAVID J

IPC: C07D495/04 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D475/06 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Abstract translation: 公开了有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。 本发明还涉及包含这些化合物的组合物，这些化合物与其它抗病毒剂或治疗剂的共同配制或共同给药，用于合成这些化合物的方法和中间体，以及使用这些化合物治疗 HCV或其他病毒感染。

公开(公告)号：AU2014280939A1

公开(公告)日：2015-01-22

申请号：AU2014280939

申请日：2014-12-24

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAUGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

公开(公告)号：CA2699989C

公开(公告)日：2014-03-25

申请号：CA2699989

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L ,  RANDOLPH JOHN T ,  KRUEGER ALLAN C ,  BETEBENNER DAVID A ,  HUTCHINSON DOUGLAS K ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  PRATT JOHN K ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK THADDEUS S II ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61P31/14 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

公开(公告)号：ES2414934T3

公开(公告)日：2013-07-23

申请号：ES11160830

申请日：2010-06-10

Applicant: ABBOTT LAB ,  ABBVIE BAHAMAS LTD

Inventor： RANDOLPH JOHN T ,  DEGOEY DAVID A ,  KATI WARREN M ,  HUTCHINS CHARLES W ,  DONNER PAMELA L ,  KRUEGER ALLAN C ,  MOTTER CHRISTOPHER E ,  NELSON LISSA T ,  PATEL SACHIN V ,  MATULENKO MARK A ,  KEDDY RYAN G ,  JINKERSON TAMMIE K ,  HUTCHINSON DOUGLAS K ,  FLENTGE CHARLES A ,  WAGNER CHARLES A ,  MARING CLARENCE J ,  TUFANO MICHAEL D ,  BETEBENNER DAVID A ,  ROCKWAY TODD W ,  LIU DACHUN ,  PRATT JOHN K ,  SARRIS KATHY ,  WOLLER KEVIN R ,  WAGAW SEBLE H ,  CALIFANO JEAN C ,  LI WENKE ,  CASPI DANIEL D ,  BELLIZZI MARY E ,  YI GAO

IPC: C07D403/14 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/4439 ,  A61P31/14 ,  C07D401/14 ,  C07D417/14

Abstract: Un compuesto de Fórmula I, o una sal farmacéuticamente aceptable del mismo,**Fórmula** donde: X es donde el átomo de nitrógeno del anillo está unido directamente a -L3-D, y donde X está opcionalmentesustituido uno o más A; L1, L2 y L3 son enlaces; cada uno de A y B es independientemente **Fórmula** y cada uno está opcional e independientemente sustituido con uno o más RA; D es carbociclo C3-C12 o heterociclo de 3 a 12 miembros, y está opcionalmente sustituido con uno o más RA;Y es -G-C(R1R2)N(R5)-T-RD, -G-C(R3R4)C(R6R7)-T-RD, N(RB)C(O)C(R1R2)N(R5)-T-RD, o N(RB)C(O)C(R3R4)C(R6R7)-T-RD; Z es -G-C(R8R9)N(R12)-T-RD, -G-C(R10R11)C(R13R14)-T-RD, -N(RB)C(O)C(R8R9)N(R12)-T-RD o N(RB)C(O)C(R10R11)C(R13R14)-T-RD; R1 es RC, y R2 y R5, tomados junto con los átomos a los que están acoplados, forman un heterociclo de 3 a 12miembros que está opcionalmente sustituido con uno o más RA.

公开(公告)号：AU2013202002A1

公开(公告)日：2013-04-18

申请号：AU2013202002

申请日：2013-03-26

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAIGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4 dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E) N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl phenyl)methanesulfonamide.